产品
编 号：F741873
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1000676-41-4
产品详情
生物活性：
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.
体内研究：
Lirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor.Animal Model:Rag1KO-Tg KIR mice injected with tumor cells
Dosage:15 mg/kg
Administration:intravenous injection; 15 mg/kg; once
Result:Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.
体内研究：
Lirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor.Animal Model:Rag1KO-Tg KIR mice injected with tumor cells
Dosage:15 mg/kg
Administration:intravenous injection; 15 mg/kg; once
Result:Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备